Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPAND-1: ANV600 alone or with pembrolizumab in advanced solid tumors
NL-OMON59738Phase 2Completed
- Sponsor
- Anaveon
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ANV600 and pembrolizumab in Nonhematologic neoplasms (2 arms), sponsored by Anaveon. Primary endpoints: Incidence of dose-limiting toxicities, Frequency and severity of treatment-emergent adverse events and 2 more. Started Sep 2024; status: completed.
02
Drugs
ANV600pembrolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON59738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59738.